This clinical trial is focused on studying a condition known as chronic pruritus of unknown origin (CPUO), which is a persistent itch without a known cause. The trial aims to evaluate the effectiveness and safety of a medication called dupilumab, which is administered as a solution for injection. The study will also involve a comparison with a placebo to assess the true effects of the medication.

The purpose of the study is to determine how well dupilumab can reduce the sensation of itch in adults suffering from CPUO. Participants in the study will receive either the medication or a placebo and will be monitored over a period of time to observe any changes in their symptoms. The study will also include the use of other medications like fexofenadine and loratadine, which are commonly used antihistamines, to see how they interact with the treatment.

Throughout the study, participants will be asked to report on their itch levels and any changes they experience. The trial will last for several weeks, with regular check-ins to track progress and ensure safety. The ultimate goal is to find a more effective way to manage and relieve the symptoms of CPUO, improving the quality of life for those affected by this challenging condition.